Ullmann Wealth Partners Group LLC Grows Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Ullmann Wealth Partners Group LLC raised its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.6% during the third quarter, Holdings Channel.com reports. The fund owned 1,329 shares of the medical equipment provider’s stock after purchasing an additional 21 shares during the quarter. Ullmann Wealth Partners Group LLC’s holdings in Intuitive Surgical were worth $653,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of ISRG. Creekmur Asset Management LLC increased its position in shares of Intuitive Surgical by 200.0% in the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 42 shares during the period. Ridgewood Investments LLC purchased a new position in shares of Intuitive Surgical in the second quarter valued at about $26,000. Delos Wealth Advisors LLC increased its position in shares of Intuitive Surgical by 380.0% in the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 57 shares during the period. LRI Investments LLC purchased a new position in shares of Intuitive Surgical during the first quarter valued at about $30,000. Finally, LGT Financial Advisors LLC increased its position in shares of Intuitive Surgical by 415.4% during the second quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 54 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Price Performance

Intuitive Surgical stock traded down $9.14 during midday trading on Tuesday, reaching $478.47. 1,312,446 shares of the company traded hands, compared to its average volume of 1,465,410. The firm has a market capitalization of $169.71 billion, a price-to-earnings ratio of 88.02, a price-to-earnings-growth ratio of 5.40 and a beta of 1.39. The business has a 50 day moving average of $481.33 and a two-hundred day moving average of $435.81. Intuitive Surgical, Inc. has a 12 month low of $254.85 and a 12 month high of $496.48.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.24. The company had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The firm’s revenue for the quarter was up 14.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.18 earnings per share. As a group, equities analysts forecast that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Analysts Set New Price Targets

ISRG has been the topic of several research analyst reports. JPMorgan Chase & Co. boosted their price target on shares of Intuitive Surgical from $495.00 to $575.00 and gave the company an “overweight” rating in a research report on Friday. Citigroup boosted their price target on shares of Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Truist Financial boosted their price target on shares of Intuitive Surgical from $520.00 to $570.00 and gave the company a “buy” rating in a research report on Monday. Stifel Nicolaus boosted their price target on shares of Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a research report on Friday, July 19th. Finally, BTIG Research boosted their price objective on shares of Intuitive Surgical from $494.00 to $518.00 and gave the stock a “buy” rating in a research note on Monday. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $467.55.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, Director Craig H. Barratt sold 1,400 shares of the company’s stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total transaction of $641,382.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Intuitive Surgical news, Director Craig H. Barratt sold 1,400 shares of the company’s stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total transaction of $641,382.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Henry L. Charlton sold 40,243 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the sale, the senior vice president now directly owns 3,001 shares of the company’s stock, valued at approximately $1,461,006.84. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 53,120 shares of company stock worth $25,528,753 over the last quarter. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.